Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 15/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19347291 | 0.91 | EGLN1 (0.71) | EGLN1PKMALDH1A1KDRKMT2A | |
| SCHEMBL19347293 | 0.88 | EGLN1 (0.69) | EGLN1PKMALDH1A1KDRKMT2A | |
| SCHEMBL19347294 | 0.88 | EGLN1 (0.60) | EGLN1PKMALDH1A1KDR | |
| SCHEMBL7684681 | 0.86 | EGLN1 (0.66) | EGLN1PKMALDH1A1KDRKMT2A | |
| SCHEMBL7686835 | 0.86 | EGLN1 (0.69) | EGLN1PKMALDH1A1KDRKMT2A | |
| SCHEMBL19347365 | 0.86 | EGLN1 (0.69) | EGLN1PKMALDH1A1KDRKMT2A | |
| SCHEMBL19347366 | 0.83 | EGLN1 (1.00) | EGLN1PKMALDH1A1 | |
| Hydrochloric Acid SCHEMBL7689316 | 0.82 | EGLN1 (0.98) | EGLN1PKMALDH1A1 | |
| SCHEMBL19347292 | 0.82 | EGLN1 (0.60) | EGLN1PKMALDH1A1KDRKMT2A | |
| SCHEMBL7692160 | 0.77 | KDR (0.74) | EGLN1ALDH1A1KDRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210205292-A1 | INHIBITORS OF CREB-CBP INTERACTION FOR TREATMENT OF LEUKEMIA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-07-08 | — | — | US | disclosed |
| WO-2017156489-A1 | INHIBITORS OF CREB-CBP INTERACTION FOR TREATMENT OF LEUKEMIA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205292-A1 | INHIBITORS OF CREB-CBP INTERACTION FOR TREATMENT OF LEUKEMIA | CREBBP, CREB1, EP300 | EGLN1 237/4885PKM 3706/4885ALDH1A1 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.